Therapeutic Discovery Platforms Bi-Weekly Industry Events & M&A Update — September 14–28, 2026

Read the report

SlidesScroll

1 of 7

←→Full screen

BI-WEEKLY INDUSTRY EVENTS & M&A UPDATE

HEALTH CARE › PHARMACEUTICALS, BIOTECHNOLOGY AND LIFE SCIENCES › THERAPEUTIC DISCOVERY PLATFORMS

Strategy Resets Reprice the Platform, Not Just the Pipeline

What moved, what companies announced, and what the transaction record showed across September 14–28, 2026.

September 14–28, 2026

Prepared by NeuraCap AI · Confidential

Market data through 2026-09-28 · events and transactions from the two-week period 2026-09-14 → 2026-09-28

Therapeutic Discovery Platforms Bi-Weekly Update | September 14–28, 2026 | Confidential | Not investment advice

Sources & methodology

1

← Previous

1 / 7 · HEALTH CARE › PHARMACEUTICALS, BIOTECHNOLOGY AND LIFE SCIENCES › THERAPEUTIC DISCOVERY PLATFORMS

Next →

What each page shows

The analyst’s walkthrough of the deck, page by page.

1. 01
   BI-WEEKLY INDUSTRY EVENTS & M&A UPDATE

   HEALTH CARE › PHARMACEUTICALS, BIOTECHNOLOGY AND LIFE SCIENCES › THERAPEUTIC DISCOVERY PLATFORMS

   Cover slide identifying the report as NeuraCap's bi-weekly industry events and M&A update for Therapeutic Discovery Platforms, September 14–28, 2026.

   This is our bi-weekly read on Therapeutic Discovery Platforms for September 14–28, 2026. Over the next few pages we cover what moved, what companies announced, and what transacted, so you leave with a clear read on what it means.

   Everything on this page

   BI-WEEKLY INDUSTRY EVENTS & M&A UPDATE HEALTH CARE › PHARMACEUTICALS, BIOTECHNOLOGY AND LIFE SCIENCES › THERAPEUTIC DISCOVERY PLATFORMS Strategy Resets Reprice the Platform, Not Just the Pipeline What moved, what companies announced, and what the transaction record showed across September 14–28, 2026. September 14–28, 2026 Prepared by NeuraCap AI · Confidential Market data through 2026-09-28 · events and transactions from the two-week period 2026-09-14 → 2026-09-28 Therapeutic Discovery Platforms Bi-Weekly Update | September 14–28, 2026 | Confidential | Not investment advice Sources & methodology 1

2. 02
   THE BI-WEEKLY BOTTOM LINE

   Every Covered Name Fell While the Broad Market Climbed

   The two-week period summarized on one page: all covered names fell while the broad market rose.

   Every one of the 6 covered names fell over the period, with a median move of -8.2%, while the S&P 500 returned +0.8% over the same two weeks. That gap tells us this was a company-driven period, not a market-driven one. Cellectis S.A. (CLLS) carried the largest decline at -19.1% after a board-approved strategic shift, and Benitec Biopharma Inc. (BNTC) followed at -17.1% despite reporting results. So the story here is dispersion within the group, not a sector-wide selloff.

   Everything on this page

   THE BI-WEEKLY BOTTOM LINE Every Covered Name Fell While the Broad Market Climbed The two-week period in one page · 6 covered names, close-to-close · September 14–28, 2026 Source: NeuraCap analytics platform (universe, prices, filings, transaction records); publisher-sourced news where linked; market data through 2026-09-28. Driver attributions use calibrated language and are NeuraCap reads of the recorded evidence. Therapeutic Discovery Platforms Bi-Weekly Update | September 14–28, 2026 | Confidential | Not investment advice Sources & methodology 2 1 The Whole Covered Set Moved Down Together 6 of 6 covered names fell; the median move was -8.2%. The S&P 500 returned +0.8% over the same two-week period. 2 A Modality Pivot Carried the Period's Largest Decline Cellectis S.A. (CLLS) ended the two-week period at -19.1%, with its worst single day at -14.3% on Sep 16. The board approved a strategic transformation into an in vivo gene editing company on Sep 14. 3 Clinical Progress Did Not Hold the Quote at Benitec Benitec Biopharma Inc. (BNTC) finished at -17.1%, with -10.2% on Sep 23, after reporting full-year results and an operational update on Sep 14. 4 The Transaction Record Added Nothing New to Price Against No new sector transactions landed in the window, so the reference set still rests on the standing lens: EV / Revenue on CY2027E, with a sector median of 2.7x. -1.1% Best mover — Denali Therapeutics Inc. (DNLI) worst: CLLS -19.1% · 0 up / 6 down of 6 covered -8.2% Sector median two-week return vs S&P 500 +0.8%

3. 03
   PUBLIC MARKET MOVERS

   Two Big Declines, Both with a Stated Cause on the Record

   The period's two largest declines both tie to a disclosed event on the record.

   Cellectis S.A. (CLLS) closed the window at -19.1%, including a single worst day of -14.3% on Sep 16, tied to a board-approved move into in vivo gene editing. Benitec Biopharma Inc. (BNTC) finished at -17.1%, with -10.2% of that move landing on Sep 23 after a full-year results release. Both moves sit well past our materiality bar of 12.4%, so we treat them as genuinely event-driven rather than noise. That means the record supports a read, not just a correlation, on why these two names moved.

   Everything on this page

   PUBLIC MARKET MOVERS Two Big Declines, Both with a Stated Cause on the Record Bi-Weekly moves, close-to-close · September 14–28, 2026 · sector median -8.2% · S&P 500 +0.8% · materiality bar ±12.4% (sector-relative) Source: NeuraCap analytics platform (universe, prices, filings, transaction records); publisher-sourced news where linked; market data through 2026-09-28. Attribution links each move only to filings and headlines recorded in the window; where no driver is recorded, the page says so. Calibrated language throughout — NeuraCap reads, not asserted causation. Therapeutic Discovery Platforms Bi-Weekly Update | September 14–28, 2026 | Confidential | Not investment advice Sources & methodology 3 Bi-Weekly return per company · teal above zero, amber below · sector median -8.2% Cellectis S.A. (CLLS) -19.1% The move appears to reflect the Sep 14 announcement that the board approved a strategic transformation into an in vivo gene editing company. Securities-fraud investigations were announced from Sep 16, the stock's worst day at -14.3%. A mid-course modality switch can reprice a Discount-tier platform faster than the new pipeline can be assessed. COMPANY-SPECIFIC Benitec Biopharma Inc. (BNTC) -17.1% Shares moved following the Sep 14 full-year 2026 results and operational update, which reported Cohort 2 of BB-301 fully enrolled and dosed. A Sep 21 preview of the Q4 print carried a consensus loss of $0.2686 per share. Enrolment progress alone does not carry a Core-tier quote when the market prices the next financing beside the next readout. COMPANY-SPECIFIC

4. 04
   MAJOR NEWS & INDUSTRY CATALYSTS

   One Strategy Reset Set the Agenda for the Whole Window

   One strategic announcement set the tone for the period's news flow.

   The highest-impact event of the window was Cellectis's board-approved transformation into an in vivo gene editing company, announced Sep 14. Benitec Biopharma Inc. also delivered a full-year results and operational update the same day, giving the market two disclosed reference points in a single session. Together these events explain why the period's two largest price moves both had a stated cause on the record. So when a client asks why the group moved, we can point to specific filings and dates, not speculation.

   Everything on this page

   MAJOR NEWS & INDUSTRY CATALYSTS One Strategy Reset Set the Agenda for the Whole Window The two-week period's highest-impact events · titles link to the underlying filing or article · September 14–28, 2026 Source: NeuraCap analytics platform (universe, prices, filings, transaction records); publisher-sourced news where linked; market data through 2026-09-28. "Why it matters" lines are NeuraCap reads; each event links to its source. Sources are admitted in a fixed reliability order (SEC filings, press releases, established outlets); video and social platforms are never used. Therapeutic Discovery Platforms Bi-Weekly Update | September 14–28, 2026 | Confidential | Not investment advice Sources & methodology 4 Sep 14 · NEWS · GlobeNewsWire Cellectis board approved a strategic transformation into an in vivo gene editing company A board-level modality switch resets which programmes carry value and which platform capacity is reusable. It puts the question of platform breadth versus single-asset dependency directly in front of the sector. When a platform changes modality, the market re-prices the engine before it re-prices any asset. Sep 25 · NEWS · PRNewsWire Nektar Therapeutics granted inducement stock options to newly hired employees Inducement grants are made to bring people in from outside. The action signals Nektar Therapeutics (NKTR) is still adding to its research organisation while peers reset strategy. Hiring into the platform is one observable read on whether candidate cadence is being defended. Sep 24 · NEWS · PRNewsWire A shareholder law firm announced an investigation of claims on behalf of Cellectis investors Legal scrutiny following a strategy announcement adds a cost and time overhang while the new pipeline is being set. It sits alongside, not instead of, the operating story. Disclosure around a pipeline exit draws attention well after the announcement date. Sep 22 · NEWS · GlobeNewsWire A further investigation into Cellectis disclosures was announced days after the strategy reset Repeat filings from separate firms extend the window in which the reset stays in the headlines rather than in the data package. The news cycle around a strategy change can outlast the announcement itself. Sep 19 · NEWS · Business Wire Another fraud investigation into Cellectis was announced, inviting shareholders to join Steady investigation traffic through the period kept the reset, rather than the new in vivo programmes, as the dominant item on the name. Attention spent on the exit is attention not yet spent on the incoming programmes. Sep 17 · NEWS · Business Wire An investigation on behalf of Cellectis investors was announced on Sep 17 The clustering of announcements on a single date shows how quickly a modality change becomes a disclosure question for a dual-listed issuer. Dual-listed platform names carry a different shareholder register and a different response pattern.

5. 05
   M&A & STRATEGIC ACTIVITY

   A Quiet Window for Transactions Leaves the Standing Lens in Place

   No new sector transactions closed in the window, so the standing valuation lens carries forward unchanged.

   The two-week period added no new sector transactions, so we're still working from the standing lens: EV / Revenue on CY2027E, with a sector median of 2.7x. Our precedent set behind that lens holds 40 recorded deals, giving the multiple real depth even without a fresh data point this period. That quiet doesn't mean nothing is happening — it means the next transaction, whenever it lands, will be judged against this same reference. For now, valuation conversations should anchor to the existing comps rather than wait for new prints.

   Everything on this page

   M&A & STRATEGIC ACTIVITY A Quiet Window for Transactions Leaves the Standing Lens in Place September 14–28, 2026 · precedent transactions: 40 recorded deals Source: NeuraCap analytics platform (universe, prices, filings, transaction records); publisher-sourced news where linked; market data through 2026-09-28. Deal multiples are LTM at announcement where disclosed; "why the deal happened" is a NeuraCap read of the recorded evidence. No old transactions are re-presented as news. Therapeutic Discovery Platforms Bi-Weekly Update | September 14–28, 2026 | Confidential | Not investment advice Sources & methodology 5 No Material Transactions Announced No material sector transactions were announced during the period. With no new precedent added, the set is still read against the standing lens of EV / Revenue on CY2027E, where the sector median is 2.7x and the Discount tier sits at a 0.8x median. A quiet two-week period is information: buyer appetite, financing conditions and seller expectations all read through a period with no new deals. The precedent transactions alongside still frame what buyers have paid. 40 Recorded precedent transactions the reference set buyers and sellers price against

6. 06
   WHAT IT MEANS

   What This Two-Week Period Changes for the People Who Run, Buy and Advise These Platforms

   What the period's moves and the unchanged deal record imply for operators, acquirers and advisors.

   For owners and operators, both large price moves this period were priced off operating news, not the market, which is a reminder that the operating clock is what's being read right now. For acquirers, no new transactions moved the reference set, so the comparison set — a 2.7x sector median EV/Revenue and a 0.8x median at the Discount tier — is unchanged in substance even as one Discount-tier platform's asset base shifted. For advisors, the period's theme is a strategy reset repricing a platform ahead of new clinical evidence, so we'd lead conversations with that reset before the underlying data package. So the read-through is the same across audiences: watch company decisions first, deal comps second.

   Everything on this page

   WHAT IT MEANS What This Two-Week Period Changes for the People Who Run, Buy and Advise These Platforms The two-week period translated for the people who act on it · NeuraCap view · observations, not recommendations Source: NeuraCap analytics platform (universe, prices, filings, transaction records); publisher-sourced news where linked; market data through 2026-09-28. This page is analytical interpretation drawn from the two-week period's recorded evidence. It is not investment advice. Therapeutic Discovery Platforms Bi-Weekly Update | September 14–28, 2026 | Confidential | Not investment advice Sources & methodology 6 Sector study 2026-09-28 EV / Revenue (CY2027E) median 2.7x 7 companies in the study 3 valuation tiers Standing thesis: Therapeutic Discovery Platforms Sit in One Segment, and the Market Prices Each Platform Separately FOR OWNERS & OPERATORS The Operating Clock Is the One the Market Is Reading Both big movers were priced off operating news: a board-approved modality change at Cellectis S.A. (CLLS) and a full-year update at Benitec Biopharma Inc. (BNTC). FOR ACQUIRERS No New Transactions Moved the Reference Set The period added no sector transactions, so the comparison set is unchanged in substance: EV / Revenue on CY2027E, a sector median of 2.7x, and a Discount tier at a 0.8x median. What did change is one Discount-tier platform's asset base, with Cellectis S.A. FOR ADVISORS Lead with the Reset, Then with the Data Package The theme of the two-week period is a strategy reset repricing a platform ahead of any new clinical evidence. Lead with the Sep 14 Cellectis announcement and the dosing and follow-up progress Benitec Biopharma Inc.

7. 07
   SOURCES & METHODOLOGY

   Sources, Methodology and Important Notice

   Explains the sources behind every figure in the update and how driver attributions are built.

   Every figure in this update ties back to a recorded filing, publisher-sourced news item, or market price through Sep 28, 2026. Where we attribute a price move to an event, that's a calibrated NeuraCap read of the recorded evidence, not an asserted cause — and where no driver is on the record, we say so directly. This discipline is what lets you trust the two big moves we highlighted this period as genuinely event-linked rather than assumed. So you can trace any number on these pages back to its source before acting on it.

   Everything on this page

   SOURCES & METHODOLOGY Sources, Methodology and Important Notice How this bi-weekly update is built and what each kind of statement rests on · September 14–28, 2026 · market data through 2026-09-28 Every figure in this update links to the record it was taken from; the publishers and filings drawn on for the period are listed above. Therapeutic Discovery Platforms Bi-Weekly Update | September 14–28, 2026 | Confidential | Not investment advice 7 OBSERVED DATA Bi-Weekly stock moves are computed close-to-close over the stated window from the platform’s price series. Deal records, values and multiples come from the platform’s transaction record (SEC 8-K extractions) exactly as recorded; each figure links to its citation. Treasury rates come from the platform’s Treasury series and are shown only when the 10-year moved at least ten basis points over the window (it did not in this window, so no rate figures appear). UNIVERSE QUALITY The update universe is the platform’s approved company set for this sector, subject to a $100M market-cap floor so small, loosely related names cannot dominate the statistics. 2 names below the floor were excluded from movers and statistics for this window. EVENTS & NEWS Company events are in-window 8-K filings; news items are publisher-sourced headlines fetched for the window (and any externally supplied items, marked as such). Operational and strategic developments (deals, partnerships, launches, expansion, guidance, leadership, regulatory outcomes) are shown first; capital-return mechanics and conference appearances are limited to one each. Every event links to its source. The deck never asserts an event that has no linked record. SOURCE HIERARCHY News is admitted in a fixed order of reliability: SEC filings first, then company press releases and investor-relations communications, then transaction documents, then established outlets (Reuters, CNBC, The Wall Street Journal, Barron’s and peers). Video and social platforms — including YouTube — are never used as sources. DRIVER ATTRIBUTION A stock move is linked to an event only when the event falls inside the window, and only in calibrated language ("the move appears to reflect…", "shares moved following…"). Where no driver is recorded, the page says so and compares the move to the sector median instead. ANALYTICAL INTERPRETATION "Why it matters", "why the deal happened" and the what-it-means page are NeuraCap analytical views drawn from the recorded evidence, and are labeled as such. INHERITED CONTEXT The standing sector view (thesis, valuation lens, sector median and tiering) is inherited from the NeuraCap sector study run_20260929T190708Z_569_prod (market data as of 2026-09-28) — distilled, never re-derived. That report’s own sources page governs its content; this update reads the period against it. IMPORTANT NOTICE This report is informational only. It is not investment advice, not a recommendation to buy or sell any security, and not an offer of any kind. Readers should perform their own diligence before acting on anything described here. Linked sources this two-week period: globenewswire.com · prnewswire.com · businesswire.com

More coverage in Health Care

• Sector Report · Sep 28, 2026Therapeutic Discovery Platforms Sector Outlook — September 2026
• Sector Report · Sep 28, 2026Medical Devices Sector Outlook — September 2026
• Bi-Weekly Update · Sep 28, 2026Medical Imaging Equipment Bi-Weekly Industry Events & M&A Update — September 14–28, 2026
• Sector Report · Sep 28, 2026Managed Health Care Sector Outlook — September 2026